Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease

Hormone Research

Volumn 64, Issue 4, 2005, Pages 189-197

  Bossowski, Artur ^a   Stasiak Barmuta, Anna ^a   Urban, Mirosława ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antithyroid antibodies; Children; Costimulatory molecules; Graves' disease

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; THIAMAZOLE; THYROTROPIN RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COULTER COUNTER; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHOOL CHILD; SEX DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; CHILD; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; IODIDE PEROXIDASE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; METHIMAZOLE; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 27844528475     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088875     Document Type: Article

References (36)

1. Ajjan RA, Kemp EH, Waterman EA, Watson PF, Endo T, Onaya T, Weetman AP: Detection of binding and blocking autoantibodies to the human sodium-iodine symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 2000;85:2020-2027.
2. Akamizu T, Moriyama K, Miura M, Saijo M, Matsuda F, Nakao K: Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology 1999;140:1594-1601.
3. Wallaschofski H, Paschke R: Detection of thyroid stimulating (TSAB) and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Clin Endocrinol (Oxf) 1999;50:365-372.
4. Bolton J, Sanders J, Oda Y, Chapman C, Konno R, Furmaniak J, Rees Smith B: Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA. Clin Chem 1999;45:2285-2287.
5. Kakinuma A, Morimoto I, Kuroda T, Fujihira T, Eto S, McLachlan SM, Rapoport B: Comparison of recombinant human thyrotropin receptors versus porcine thyrotropin receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies. Thyroid 1999;9:849-855.
6. Eguchi K, Matsuoka N, Nagataki S: Cellular immunity in autoimmune thyroid disease. Baillieres Clin Endocrinol Metab 1995;9:71-94.
7. Pozzilli P, Carotenuto P, Delitala G: Lymphocytic traffic and homing into target tissue and the generation of endocrine autoimmunity. Clin Endocrinol (Oxf) 1994;41:545-554.
8. Marazuela M: Lymphocyte traffic and homing in autoimmune thyroid disorders. Eur J Endocrinol 1999;140:287-290.
9. Roura-Mir IC, Alcalde L, Vargas F, Tolosa E, Obiols G, Foz M, Jaraquemada D, Pujol-Borrell R: γ/δ Lymphocytes in endocrine autoimmunity: evidence of expansion in Graves' disease but not in type 1 diabetes. Clin Exp Immunol 1993;92:288-295.
10. Bossowski A, Urban M, Stasiak-Barmuta A: Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, subsets CD4, CD8 and their memory (CD45RO), and naive (CD45RA) T cells in children with immune and non-immune thyroid diseases. J Pediatr Endocrinol Metab 2003;16:63-70.
11. Bossowski A, Urban M, Stasiak-Barmuta A: Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease. Pediatr Res 2003;54:425-429.
12. Fujikawa M, Okamura K, Sato K, Mizokami T, Tanabe S, Ikenoue H, Okamura S, Ohta M, Fujishima M: Usefulness of surface phenotype study of intrathyroidal lymphocytes obtained by fine needle aspiration cytology in autoimmune thyroid disease and malignant lymphoma of the thyroid. Clin Endocrinol (Oxf) 1998;49:191-196.
13. Sansom DM, Hall ND: B7/BB1, the ligand for CD28, is expressed on repeatedly activated human cells in vitro. Eur J Immunol 1993;23:295-298.
14. Wyss-Coray T, Mauri-Hellweg D, Baumann K, Bettens F, Grunow R, Pichler WJ: The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions. Eur J Immunol 1993;23:2175-2180.
15. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7.1 and B7.2 co-stimulatory molecules differentially activate the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-718.
16. Damle NK, Klussman K, Leytze G, Myrdal S, Aruffo A, Ledbetter JA, Linsley PS: Co-stimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol 1994;152:2686-2697.
17. Tomer Y, Greenberg DA, Barbesino G, Conception E, Davies TF: CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001;86:1687-1693.
18. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SH: The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 1999;8:1195-1199.
19. Heward J, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard M, Holder RL, Barnett AH, Franflyn JA, Gough SC: The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999;84:2398-2401.
20. Park Y, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, Cho BY: Polymorphism in the promotor and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 2000;10:453-459.
21. Zaletel K, Krhin B, Gaberscek S, Pirnat E, Hojker S: The influence of the exon 1 polymorphism of the CTLA-4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Thyroid 2002;12:373-376.
22. Kinjo Y, Takasu N, Komiya I, Tomoyose T, Takara M, Kouki T, Shimajiri Y, Yabiko K, Yoshimura H: Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of CTLA-4. J Clin Endocrinol Metab 2002;87:2593-2596.
23. Yung E, Cheng PS, Fok TF, Wong GW: CTLA-4 gene A-G polymorphism and childhood Graves' disease. Clin Endocrinol (Oxf) 2002;56:649-653.
24. Laso FJ, Madruga JI, Giron JA, Lopez A, Ciudad J, San Miguel JF, Alvarez-Mon M, Orfao A: Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 1997;25:1096-1100.
25. Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA: Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res 1998;30:162-168.
26. Eguchi K, Otsubo T, Kawabe Y, Shimomura C, Ueki Y, Nakao H, Tezuka H, Matsunaga M, Fukude T, Ishikawa N: Synergy in antigen presentation by thyroid epithelial cells and monocytes from patients with Graves' disease. Clin Exp Immunol 1988;72:84-90.
27. Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Nakamura H, Kimura H, Ishikawa N, Ito K, Nagataki S: Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. J Clin Endocrinol Metab 1996;81:4137-4143.
28. Salamaco C, Olive D, Pesce G, Bagnasco M: Costimulatory molecules and autoimmune thyroid diseases. Autoimmunity 2002;35:159-167.
29. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M: Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation 2004;11:209-213.
30. Liu MF, Yang CY, Li JS, Lai KA, Chao SC, Lei HY: Increased expression of down-regulatory CTLA-4 molecule on T lymphocytes from rheumatoid synovial compartment. Scand J Immunol 1999;50:68-72.
31. Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P: Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999;98:413-421.
32. Steiner K, Moosig F, Csernok E, Selleng K, Gross WL, Fleischer B, Broker BM: Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 2001;126:143-150.
33. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ: CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-6611.
34. Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Conception ES, Villanueva RB, Barbesino G, Ling V, Tomer Y: Analysis of the CTLA-4, CD28 and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 2003;4:586-593.
35. Weetman AP, McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15: 788-830.
36. Oaks MK, Hallett KM: Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-5018.